Economic Burden of Chronic Lymphocytic Leukaemia in Australia

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter’s transformation

Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis

Approaches to the management of relapsed/refractory mantle cell lymphoma: navigating an increasingly complex therapeutic landscape

Clinical outcomes with venetoclax-based therapy in patients with relapsed/refractory B-cell lymphomas

Pharmaceutical Benefits Advisory Committee Recommendations Announced

Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study

Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study

Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial